Here are the 424B prospectus supplements from Cencora, Inc. (COR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow COR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COR filings page.
Cencora, Inc. is issuing $3.0 billion of unsecured senior notes in five tranches maturing between 2029 and 2056, with fixed coupons ranging from 3.950% to 5.650%. Interest will be paid semi‑annually, and the notes rank equally with Cencora’s other unsecured, unsubordinated debt and are structurally subordinated to subsidiary liabilities.
Cencora expects net proceeds of about $2.98 billion, which it intends to use to repay in full its $3.0 billion 364‑Day Term Loan Facility used to help fund the approximately $4.6 billion acquisition of OneOncology, with any remaining funds for general corporate purposes.
The notes are redeemable at Cencora’s option (including make‑whole and par call structures) and must be offered for repurchase at 101% of principal plus accrued interest if a defined Change of Control Triggering Event occurs. The securities will be issued in book‑entry form and are not expected to be listed on any exchange.
Cencora, Inc. plans a multi‑tranche unsecured senior notes offering, with each series paying fixed interest semi‑annually and maturing on different future dates. The notes rank equally with Cencora’s other unsecured, unsubordinated debt and are structurally subordinated to liabilities at subsidiaries.
Cencora intends to use the net proceeds to repay in full borrowings under its $3.0 billion 364‑Day Term Loan Facility, which helped fund the approximately $4.6 billion acquisition of OneOncology, and, if any funds remain, for general corporate purposes. A change of control triggering event requires Cencora to offer to repurchase the notes at 101% of principal plus accrued interest, and the notes are redeemable at Cencora’s option subject to make‑whole and par call terms.